Chief Technology Officer: Sirnaomics Inc.
Dr. Samarsky has been at the inception of RNAi technology - starting in 2001 as Director of Technology Development at Sequitur (acquired by Invitrogen in 2003) and, in 2005, as Director of Technology Development at Dharmacon (now part of GE). He then served as VP of Technology Development at RXi Pharmaceuticals, USA (2007-2011), SVP of Technology and International Business Development at RiboBio, China (2011-2016) and as Chief Scientific Officer at Silence Therapeutics, Germany (2016-2018). Since 2018, he serves as a Chief Technology Officer at Sirnaomics (USA). Dr. Samarsky has authored more than 40 scientific papers, articles, book chapters, patents and patent applications. He has been an invited speaker at more than 100 international conferences, and currently serves on the Scientific Advisory Boards for the OTS (Oligonucleotide Therapeutics Society), CNAF (China Nucleic Acids Forum), TIDES (Oligonucleotide and Peptide Therapeutics) conference series and OPT (Oligonucleotide and Precision Therapeutics) Congress. Dr. Samarsky received his Ph.D. in biochemistry and molecular biology from University of Massachusetts, Amherst (1998), followed by a postdoctoral position as an H. Arthur Smith Fellow for Cancer Research at University of Massachusetts Medical School (1998-2001; Dr. Michael Green lab).